by dmsAdmin | Jun 18, 2020
Recently, the FDA provided approval for the use of two new PET radiopharmaceuticals, Cerianna and Tauvid. Cerianna is a molecular imaging agent indicated for use in PET imaging for the detection of estrogen receptor-positive lesions as an adjunct to biopsy in patients...
by dmsAdmin | Jun 13, 2019
Axumin (18Fluciclovine) is a radiopharmaceutical that is proving to be a game-changer, particularly in the field of prostate cancer detection. Previously, clinicians in the U.S. had little choice but to use 18FDG to perform the majority of PET/CT imaging. This has...
